Industry Research Reports

Home > Reports > Medical Care > Carbapenem-Based Antibiotics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Carbapenem-Based Antibiotics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Industry: Medical Care

Published: 2024-01-11

Pages: 103 Pages

Report ld: 2639006

Description
Table of Contents
Table of Figures
PDF Download

Description
Table of Contents
Table of Figures
PDF Download

Description

The global market for Carbapenem-Based Antibiotics was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

North American market for Carbapenem-Based Antibiotics was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Carbapenem-Based Antibiotics was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Europe market for Carbapenem-Based Antibiotics was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The global key companies of Carbapenem-Based Antibiotics include ACS Dobfar S.p.A, Iterum Therapeutics plc, DAEWOONG PHARMACEUTICAL CO.,LTD, Aurobindo Pharma Ltd, Gland Pharma Limited, Merck & Co., Inc., Sumitomo Dainippon Pharma Co., Ltd., Savior Lifetec and Pfizer Inc., etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Carbapenem-Based Antibiotics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Carbapenem-Based Antibiotics by region & country, by Type, and by Application.

The Carbapenem-Based Antibiotics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Carbapenem-Based Antibiotics.

Market Segmentation

Report Metric
Details
Report Title
Carbapenem-Based Antibiotics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Global Carbapenem-Based Antibiotics Companies Covered
ACS Dobfar S.p.A, Iterum Therapeutics plc, DAEWOONG PHARMACEUTICAL CO.,LTD, Aurobindo Pharma Ltd, Gland Pharma Limited, Merck & Co., Inc., Sumitomo Dainippon Pharma Co., Ltd., Savior Lifetec, Pfizer Inc., Spero Therapeutics
Global Carbapenem-Based Antibiotics Market, by Region
North America (U.S., Canada, Mexico)

Europe (Germany, France, UK, Italy, etc.)

Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)

South America (Brazil, etc.)

Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Carbapenem-Based Antibiotics Market, Segment by Type
Meropenem

Doripenemu

Imipenem

Tebipenemu

Others
Global Carbapenem-Based Antibiotics Market, Segment by Application
Retail Pharmacies

Online Pharmacies

Hospital Pharmacies
Forecast Units
USD million in value
Report Coverage
Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Carbapenem-Based Antibiotics manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Carbapenem-Based Antibiotics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Carbapenem-Based Antibiotics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Table of Contents

 1 Market Overview
    1.1 Carbapenem-Based Antibiotics Product Introduction
    1.2 Global Carbapenem-Based Antibiotics Market Size Forecast
    1.3 Carbapenem-Based Antibiotics Market Trends & Drivers
        1.3.1 Carbapenem-Based Antibiotics Industry Trends
        1.3.2 Carbapenem-Based Antibiotics Market Drivers & Opportunity
        1.3.3 Carbapenem-Based Antibiotics Market Challenges
        1.3.4 Carbapenem-Based Antibiotics Market Restraints
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

 2 Competitive Analysis by Company
    2.1 Global Carbapenem-Based Antibiotics Players Revenue Ranking (2023)
    2.2 Global Carbapenem-Based Antibiotics Revenue by Company (2019-2024)
    2.3 Key Companies Carbapenem-Based Antibiotics Manufacturing Base Distribution and Headquarters
    2.4 Key Companies Carbapenem-Based Antibiotics Product Offered
    2.5 Key Companies Time to Begin Mass Production of Carbapenem-Based Antibiotics
    2.6 Carbapenem-Based Antibiotics Market Competitive Analysis
        2.6.1 Carbapenem-Based Antibiotics Market Concentration Rate (2019-2024)
        2.6.2 Global 5 and 10 Largest Companies by Carbapenem-Based Antibiotics Revenue in 2023
        2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Carbapenem-Based Antibiotics as of 2023)
    2.7 Mergers & Acquisitions, Expansion

 3 Segmentation by Type
    3.1 Introduction by Type
        3.1.1 Meropenem
        3.1.2 Doripenemu
        3.1.3 Imipenem
        3.1.4 Tebipenemu
        3.1.5 Others
    3.2 Global Carbapenem-Based Antibiotics Sales Value by Type
        3.2.1 Global Carbapenem-Based Antibiotics Sales Value by Type (2019 VS 2023 VS 2030)
        3.2.2 Global Carbapenem-Based Antibiotics Sales Value, by Type (2019-2030)
        3.2.3 Global Carbapenem-Based Antibiotics Sales Value, by Type (%) (2019-2030)

 4 Segmentation by Application
    4.1 Introduction by Application
        4.1.1 Retail Pharmacies
        4.1.2 Online Pharmacies
        4.1.3 Hospital Pharmacies
    4.2 Global Carbapenem-Based Antibiotics Sales Value by Application
        4.2.1 Global Carbapenem-Based Antibiotics Sales Value by Application (2019 VS 2023 VS 2030)
        4.2.2 Global Carbapenem-Based Antibiotics Sales Value, by Application (2019-2030)
        4.2.3 Global Carbapenem-Based Antibiotics Sales Value, by Application (%) (2019-2030)

 5 Segmentation by Region
    5.1 Global Carbapenem-Based Antibiotics Sales Value by Region
        5.1.1 Global Carbapenem-Based Antibiotics Sales Value by Region: 2019 VS 2023 VS 2030
        5.1.2 Global Carbapenem-Based Antibiotics Sales Value by Region (2019-2024)
        5.1.3 Global Carbapenem-Based Antibiotics Sales Value by Region (2025-2030)
        5.1.4 Global Carbapenem-Based Antibiotics Sales Value by Region (%), (2019-2030)
    5.2 North America
        5.2.1 North America Carbapenem-Based Antibiotics Sales Value, 2019-2030
        5.2.2 North America Carbapenem-Based Antibiotics Sales Value by Country (%), 2023 VS 2030
    5.3 Europe
        5.3.1 Europe Carbapenem-Based Antibiotics Sales Value, 2019-2030
        5.3.2 Europe Carbapenem-Based Antibiotics Sales Value by Country (%), 2023 VS 2030
    5.4 Asia Pacific
        5.4.1 Asia Pacific Carbapenem-Based Antibiotics Sales Value, 2019-2030
        5.4.2 Asia Pacific Carbapenem-Based Antibiotics Sales Value by Country (%), 2023 VS 2030
    5.5 South America
        5.5.1 South America Carbapenem-Based Antibiotics Sales Value, 2019-2030
        5.5.2 South America Carbapenem-Based Antibiotics Sales Value by Country (%), 2023 VS 2030
    5.6 Middle East & Africa
        5.6.1 Middle East & Africa Carbapenem-Based Antibiotics Sales Value, 2019-2030
        5.6.2 Middle East & Africa Carbapenem-Based Antibiotics Sales Value by Country (%), 2023 VS 2030

 6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions Carbapenem-Based Antibiotics Sales Value Growth Trends, 2019 VS 2023 VS 2030
    6.2 Key Countries/Regions Carbapenem-Based Antibiotics Sales Value
    6.3 United States
        6.3.1 United States Carbapenem-Based Antibiotics Sales Value, 2019-2030
        6.3.2 United States Carbapenem-Based Antibiotics Sales Value by Type (%), 2023 VS 2030
        6.3.3 United States Carbapenem-Based Antibiotics Sales Value by Application, 2023 VS 2030
    6.4 Europe
        6.4.1 Europe Carbapenem-Based Antibiotics Sales Value, 2019-2030
        6.4.2 Europe Carbapenem-Based Antibiotics Sales Value by Type (%), 2023 VS 2030
        6.4.3 Europe Carbapenem-Based Antibiotics Sales Value by Application, 2023 VS 2030
    6.5 China
        6.5.1 China Carbapenem-Based Antibiotics Sales Value, 2019-2030
        6.5.2 China Carbapenem-Based Antibiotics Sales Value by Type (%), 2023 VS 2030
        6.5.3 China Carbapenem-Based Antibiotics Sales Value by Application, 2023 VS 2030
    6.6 Japan
        6.6.1 Japan Carbapenem-Based Antibiotics Sales Value, 2019-2030
        6.6.2 Japan Carbapenem-Based Antibiotics Sales Value by Type (%), 2023 VS 2030
        6.6.3 Japan Carbapenem-Based Antibiotics Sales Value by Application, 2023 VS 2030
    6.7 South Korea
        6.7.1 South Korea Carbapenem-Based Antibiotics Sales Value, 2019-2030
        6.7.2 South Korea Carbapenem-Based Antibiotics Sales Value by Type (%), 2023 VS 2030
        6.7.3 South Korea Carbapenem-Based Antibiotics Sales Value by Application, 2023 VS 2030
    6.8 Southeast Asia
        6.8.1 Southeast Asia Carbapenem-Based Antibiotics Sales Value, 2019-2030
        6.8.2 Southeast Asia Carbapenem-Based Antibiotics Sales Value by Type (%), 2023 VS 2030
        6.8.3 Southeast Asia Carbapenem-Based Antibiotics Sales Value by Application, 2023 VS 2030
    6.9 India
        6.9.1 India Carbapenem-Based Antibiotics Sales Value, 2019-2030
        6.9.2 India Carbapenem-Based Antibiotics Sales Value by Type (%), 2023 VS 2030
        6.9.3 India Carbapenem-Based Antibiotics Sales Value by Application, 2023 VS 2030

 7 Company Profiles
    7.1 ACS Dobfar S.p.A
        7.1.1 ACS Dobfar S.p.A Profile
        7.1.2 ACS Dobfar S.p.A Main Business
        7.1.3 ACS Dobfar S.p.A Carbapenem-Based Antibiotics Products, Services and Solutions
        7.1.4 ACS Dobfar S.p.A Carbapenem-Based Antibiotics Revenue (US$ Million) & (2019-2024)
        7.1.5 ACS Dobfar S.p.A Recent Developments
    7.2 Iterum Therapeutics plc
        7.2.1 Iterum Therapeutics plc Profile
        7.2.2 Iterum Therapeutics plc Main Business
        7.2.3 Iterum Therapeutics plc Carbapenem-Based Antibiotics Products, Services and Solutions
        7.2.4 Iterum Therapeutics plc Carbapenem-Based Antibiotics Revenue (US$ Million) & (2019-2024)
        7.2.5 Iterum Therapeutics plc Recent Developments
    7.3 DAEWOONG PHARMACEUTICAL CO.,LTD
        7.3.1 DAEWOONG PHARMACEUTICAL CO.,LTD Profile
        7.3.2 DAEWOONG PHARMACEUTICAL CO.,LTD Main Business
        7.3.3 DAEWOONG PHARMACEUTICAL CO.,LTD Carbapenem-Based Antibiotics Products, Services and Solutions
        7.3.4 DAEWOONG PHARMACEUTICAL CO.,LTD Carbapenem-Based Antibiotics Revenue (US$ Million) & (2019-2024)
        7.3.5 Aurobindo Pharma Ltd Recent Developments
    7.4 Aurobindo Pharma Ltd
        7.4.1 Aurobindo Pharma Ltd Profile
        7.4.2 Aurobindo Pharma Ltd Main Business
        7.4.3 Aurobindo Pharma Ltd Carbapenem-Based Antibiotics Products, Services and Solutions
        7.4.4 Aurobindo Pharma Ltd Carbapenem-Based Antibiotics Revenue (US$ Million) & (2019-2024)
        7.4.5 Aurobindo Pharma Ltd Recent Developments
    7.5 Gland Pharma Limited
        7.5.1 Gland Pharma Limited Profile
        7.5.2 Gland Pharma Limited Main Business
        7.5.3 Gland Pharma Limited Carbapenem-Based Antibiotics Products, Services and Solutions
        7.5.4 Gland Pharma Limited Carbapenem-Based Antibiotics Revenue (US$ Million) & (2019-2024)
        7.5.5 Gland Pharma Limited Recent Developments
    7.6 Merck & Co., Inc.
        7.6.1 Merck & Co., Inc. Profile
        7.6.2 Merck & Co., Inc. Main Business
        7.6.3 Merck & Co., Inc. Carbapenem-Based Antibiotics Products, Services and Solutions
        7.6.4 Merck & Co., Inc. Carbapenem-Based Antibiotics Revenue (US$ Million) & (2019-2024)
        7.6.5 Merck & Co., Inc. Recent Developments
    7.7 Sumitomo Dainippon Pharma Co., Ltd.
        7.7.1 Sumitomo Dainippon Pharma Co., Ltd. Profile
        7.7.2 Sumitomo Dainippon Pharma Co., Ltd. Main Business
        7.7.3 Sumitomo Dainippon Pharma Co., Ltd. Carbapenem-Based Antibiotics Products, Services and Solutions
        7.7.4 Sumitomo Dainippon Pharma Co., Ltd. Carbapenem-Based Antibiotics Revenue (US$ Million) & (2019-2024)
        7.7.5 Sumitomo Dainippon Pharma Co., Ltd. Recent Developments
    7.8 Savior Lifetec
        7.8.1 Savior Lifetec Profile
        7.8.2 Savior Lifetec Main Business
        7.8.3 Savior Lifetec Carbapenem-Based Antibiotics Products, Services and Solutions
        7.8.4 Savior Lifetec Carbapenem-Based Antibiotics Revenue (US$ Million) & (2019-2024)
        7.8.5 Savior Lifetec Recent Developments
    7.9 Pfizer Inc.
        7.9.1 Pfizer Inc. Profile
        7.9.2 Pfizer Inc. Main Business
        7.9.3 Pfizer Inc. Carbapenem-Based Antibiotics Products, Services and Solutions
        7.9.4 Pfizer Inc. Carbapenem-Based Antibiotics Revenue (US$ Million) & (2019-2024)
        7.9.5 Pfizer Inc. Recent Developments
    7.10 Spero Therapeutics
        7.10.1 Spero Therapeutics Profile
        7.10.2 Spero Therapeutics Main Business
        7.10.3 Spero Therapeutics Carbapenem-Based Antibiotics Products, Services and Solutions
        7.10.4 Spero Therapeutics Carbapenem-Based Antibiotics Revenue (US$ Million) & (2019-2024)
        7.10.5 Spero Therapeutics Recent Developments

 8 Industry Chain Analysis
    8.1 Carbapenem-Based Antibiotics Industrial Chain
    8.2 Carbapenem-Based Antibiotics Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Raw Materials Key Suppliers
        8.2.3 Manufacturing Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream Analysis (Customers Analysis)
    8.5 Sales Model and Sales Channels
        8.5.1 Carbapenem-Based Antibiotics Sales Model
        8.5.2 Sales Channel
        8.5.3 Carbapenem-Based Antibiotics Distributors

 9 Research Findings and Conclusion

 10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
        10.1.2 Data Source
    10.2 Author Details
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Carbapenem-Based Antibiotics Market Trends
    Table 2. Carbapenem-Based Antibiotics Market Drivers & Opportunity
    Table 3. Carbapenem-Based Antibiotics Market Challenges
    Table 4. Carbapenem-Based Antibiotics Market Restraints
    Table 5. Global Carbapenem-Based Antibiotics Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Carbapenem-Based Antibiotics Revenue Market Share by Company (2019-2024)
    Table 7. Key Companies Carbapenem-Based Antibiotics Manufacturing Base Distribution and Headquarters
    Table 8. Key Companies Carbapenem-Based Antibiotics Product Type
    Table 9. Key Companies Time to Begin Mass Production of Carbapenem-Based Antibiotics
    Table 10. Global Carbapenem-Based Antibiotics Companies Market Concentration Ratio (CR5 and HHI)
    Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Carbapenem-Based Antibiotics as of 2023)
    Table 12. Mergers & Acquisitions, Expansion Plans
    Table 13. Global Carbapenem-Based Antibiotics Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 14. Global Carbapenem-Based Antibiotics Sales Value by Type (2019-2024) & (US$ Million)
    Table 15. Global Carbapenem-Based Antibiotics Sales Value by Type (2025-2030) & (US$ Million)
    Table 16. Global Carbapenem-Based Antibiotics Sales Market Share in Value by Type (2019-2024) & (%)
    Table 17. Global Carbapenem-Based Antibiotics Sales Market Share in Value by Type (2025-2030) & (%)
    Table 18. Global Carbapenem-Based Antibiotics Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 19. Global Carbapenem-Based Antibiotics Sales Value by Application (2019-2024) & (US$ Million)
    Table 20. Global Carbapenem-Based Antibiotics Sales Value by Application (2025-2030) & (US$ Million)
    Table 21. Global Carbapenem-Based Antibiotics Sales Market Share in Value by Application (2019-2024) & (%)
    Table 22. Global Carbapenem-Based Antibiotics Sales Market Share in Value by Application (2025-2030) & (%)
    Table 23. Global Carbapenem-Based Antibiotics Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 24. Global Carbapenem-Based Antibiotics Sales Value by Region (2019-2024) & (US$ Million)
    Table 25. Global Carbapenem-Based Antibiotics Sales Value by Region (2025-2030) & (US$ Million)
    Table 26. Global Carbapenem-Based Antibiotics Sales Value by Region (2019-2024) & (%)
    Table 27. Global Carbapenem-Based Antibiotics Sales Value by Region (2025-2030) & (%)
    Table 28. Key Countries/Regions Carbapenem-Based Antibiotics Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 29. Key Countries/Regions Carbapenem-Based Antibiotics Sales Value, (2019-2024) & (US$ Million)
    Table 30. Key Countries/Regions Carbapenem-Based Antibiotics Sales Value, (2025-2030) & (US$ Million)
    Table 31. ACS Dobfar S.p.A Basic Information List
    Table 32. ACS Dobfar S.p.A Description and Business Overview
    Table 33. ACS Dobfar S.p.A Carbapenem-Based Antibiotics Products, Services and Solutions
    Table 34. Revenue (US$ Million) in Carbapenem-Based Antibiotics Business of ACS Dobfar S.p.A (2019-2024)
    Table 35. ACS Dobfar S.p.A Recent Developments
    Table 36. Iterum Therapeutics plc Basic Information List
    Table 37. Iterum Therapeutics plc Description and Business Overview
    Table 38. Iterum Therapeutics plc Carbapenem-Based Antibiotics Products, Services and Solutions
    Table 39. Revenue (US$ Million) in Carbapenem-Based Antibiotics Business of Iterum Therapeutics plc (2019-2024)
    Table 40. Iterum Therapeutics plc Recent Developments
    Table 41. DAEWOONG PHARMACEUTICAL CO.,LTD Basic Information List
    Table 42. DAEWOONG PHARMACEUTICAL CO.,LTD Description and Business Overview
    Table 43. DAEWOONG PHARMACEUTICAL CO.,LTD Carbapenem-Based Antibiotics Products, Services and Solutions
    Table 44. Revenue (US$ Million) in Carbapenem-Based Antibiotics Business of DAEWOONG PHARMACEUTICAL CO.,LTD (2019-2024)
    Table 45. DAEWOONG PHARMACEUTICAL CO.,LTD Recent Developments
    Table 46. Aurobindo Pharma Ltd Basic Information List
    Table 47. Aurobindo Pharma Ltd Description and Business Overview
    Table 48. Aurobindo Pharma Ltd Carbapenem-Based Antibiotics Products, Services and Solutions
    Table 49. Revenue (US$ Million) in Carbapenem-Based Antibiotics Business of Aurobindo Pharma Ltd (2019-2024)
    Table 50. Aurobindo Pharma Ltd Recent Developments
    Table 51. Gland Pharma Limited Basic Information List
    Table 52. Gland Pharma Limited Description and Business Overview
    Table 53. Gland Pharma Limited Carbapenem-Based Antibiotics Products, Services and Solutions
    Table 54. Revenue (US$ Million) in Carbapenem-Based Antibiotics Business of Gland Pharma Limited (2019-2024)
    Table 55. Gland Pharma Limited Recent Developments
    Table 56. Merck & Co., Inc. Basic Information List
    Table 57. Merck & Co., Inc. Description and Business Overview
    Table 58. Merck & Co., Inc. Carbapenem-Based Antibiotics Products, Services and Solutions
    Table 59. Revenue (US$ Million) in Carbapenem-Based Antibiotics Business of Merck & Co., Inc. (2019-2024)
    Table 60. Merck & Co., Inc. Recent Developments
    Table 61. Sumitomo Dainippon Pharma Co., Ltd. Basic Information List
    Table 62. Sumitomo Dainippon Pharma Co., Ltd. Description and Business Overview
    Table 63. Sumitomo Dainippon Pharma Co., Ltd. Carbapenem-Based Antibiotics Products, Services and Solutions
    Table 64. Revenue (US$ Million) in Carbapenem-Based Antibiotics Business of Sumitomo Dainippon Pharma Co., Ltd. (2019-2024)
    Table 65. Sumitomo Dainippon Pharma Co., Ltd. Recent Developments
    Table 66. Savior Lifetec Basic Information List
    Table 67. Savior Lifetec Description and Business Overview
    Table 68. Savior Lifetec Carbapenem-Based Antibiotics Products, Services and Solutions
    Table 69. Revenue (US$ Million) in Carbapenem-Based Antibiotics Business of Savior Lifetec (2019-2024)
    Table 70. Savior Lifetec Recent Developments
    Table 71. Pfizer Inc. Basic Information List
    Table 72. Pfizer Inc. Description and Business Overview
    Table 73. Pfizer Inc. Carbapenem-Based Antibiotics Products, Services and Solutions
    Table 74. Revenue (US$ Million) in Carbapenem-Based Antibiotics Business of Pfizer Inc. (2019-2024)
    Table 75. Pfizer Inc. Recent Developments
    Table 76. Spero Therapeutics Basic Information List
    Table 77. Spero Therapeutics Description and Business Overview
    Table 78. Spero Therapeutics Carbapenem-Based Antibiotics Products, Services and Solutions
    Table 79. Revenue (US$ Million) in Carbapenem-Based Antibiotics Business of Spero Therapeutics (2019-2024)
    Table 80. Spero Therapeutics Recent Developments
    Table 81. Key Raw Materials Lists
    Table 82. Raw Materials Key Suppliers Lists
    Table 83. Carbapenem-Based Antibiotics Downstream Customers
    Table 84. Carbapenem-Based Antibiotics Distributors List
    Table 85. Research Programs/Design for This Report
    Table 86. Key Data Information from Secondary Sources
    Table 87. Key Data Information from Primary Sources
    Table 88. Business Unit and Senior & Team Lead Analysts
List of Figures
    Figure 1. Carbapenem-Based Antibiotics Product Picture
    Figure 2. Global Carbapenem-Based Antibiotics Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Carbapenem-Based Antibiotics Sales Value (2019-2030) & (US$ Million)
    Figure 4. Carbapenem-Based Antibiotics Report Years Considered
    Figure 5. Global Carbapenem-Based Antibiotics Players Revenue Ranking (2023) & (US$ Million)
    Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Carbapenem-Based Antibiotics Revenue in 2023
    Figure 7. Carbapenem-Based Antibiotics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 8. Meropenem Picture
    Figure 9. Doripenemu Picture
    Figure 10. Imipenem Picture
    Figure 11. Tebipenemu Picture
    Figure 12. Others Picture
    Figure 13. Global Carbapenem-Based Antibiotics Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 14. Global Carbapenem-Based Antibiotics Sales Value Market Share by Type, 2023 & 2030
    Figure 15. Product Picture of Retail Pharmacies
    Figure 16. Product Picture of Online Pharmacies
    Figure 17. Product Picture of Hospital Pharmacies
    Figure 18. Global Carbapenem-Based Antibiotics Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 19. Global Carbapenem-Based Antibiotics Sales Value Market Share by Application, 2023 & 2030
    Figure 20. North America Carbapenem-Based Antibiotics Sales Value (2019-2030) & (US$ Million)
    Figure 21. North America Carbapenem-Based Antibiotics Sales Value by Country (%), 2023 VS 2030
    Figure 22. Europe Carbapenem-Based Antibiotics Sales Value (2019-2030) & (US$ Million)
    Figure 23. Europe Carbapenem-Based Antibiotics Sales Value by Country (%), 2023 VS 2030
    Figure 24. Asia Pacific Carbapenem-Based Antibiotics Sales Value (2019-2030) & (US$ Million)
    Figure 25. Asia Pacific Carbapenem-Based Antibiotics Sales Value by Country (%), 2023 VS 2030
    Figure 26. South America Carbapenem-Based Antibiotics Sales Value (2019-2030) & (US$ Million)
    Figure 27. South America Carbapenem-Based Antibiotics Sales Value by Country (%), 2023 VS 2030
    Figure 28. Middle East & Africa Carbapenem-Based Antibiotics Sales Value (2019-2030) & (US$ Million)
    Figure 29. Middle East & Africa Carbapenem-Based Antibiotics Sales Value by Country (%), 2023 VS 2030
    Figure 30. Key Countries/Regions Carbapenem-Based Antibiotics Sales Value (%), (2019-2030)
    Figure 31. United States Carbapenem-Based Antibiotics Sales Value, (2019-2030) & (US$ Million)
    Figure 32. United States Carbapenem-Based Antibiotics Sales Value by Type (%), 2023 VS 2030
    Figure 33. United States Carbapenem-Based Antibiotics Sales Value by Application (%), 2023 VS 2030
    Figure 34. Europe Carbapenem-Based Antibiotics Sales Value, (2019-2030) & (US$ Million)
    Figure 35. Europe Carbapenem-Based Antibiotics Sales Value by Type (%), 2023 VS 2030
    Figure 36. Europe Carbapenem-Based Antibiotics Sales Value by Application (%), 2023 VS 2030
    Figure 37. China Carbapenem-Based Antibiotics Sales Value, (2019-2030) & (US$ Million)
    Figure 38. China Carbapenem-Based Antibiotics Sales Value by Type (%), 2023 VS 2030
    Figure 39. China Carbapenem-Based Antibiotics Sales Value by Application (%), 2023 VS 2030
    Figure 40. Japan Carbapenem-Based Antibiotics Sales Value, (2019-2030) & (US$ Million)
    Figure 41. Japan Carbapenem-Based Antibiotics Sales Value by Type (%), 2023 VS 2030
    Figure 42. Japan Carbapenem-Based Antibiotics Sales Value by Application (%), 2023 VS 2030
    Figure 43. South Korea Carbapenem-Based Antibiotics Sales Value, (2019-2030) & (US$ Million)
    Figure 44. South Korea Carbapenem-Based Antibiotics Sales Value by Type (%), 2023 VS 2030
    Figure 45. South Korea Carbapenem-Based Antibiotics Sales Value by Application (%), 2023 VS 2030
    Figure 46. Southeast Asia Carbapenem-Based Antibiotics Sales Value, (2019-2030) & (US$ Million)
    Figure 47. Southeast Asia Carbapenem-Based Antibiotics Sales Value by Type (%), 2023 VS 2030
    Figure 48. Southeast Asia Carbapenem-Based Antibiotics Sales Value by Application (%), 2023 VS 2030
    Figure 49. India Carbapenem-Based Antibiotics Sales Value, (2019-2030) & (US$ Million)
    Figure 50. India Carbapenem-Based Antibiotics Sales Value by Type (%), 2023 VS 2030
    Figure 51. India Carbapenem-Based Antibiotics Sales Value by Application (%), 2023 VS 2030
    Figure 52. Carbapenem-Based Antibiotics Industrial Chain
    Figure 53. Carbapenem-Based Antibiotics Manufacturing Cost Structure
    Figure 54. Channels of Distribution (Direct Sales, and Distribution)
    Figure 55. Bottom-up and Top-down Approaches for This Report
    Figure 56. Data Triangulation

Description

The global market for Carbapenem-Based Antibiotics was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

North American market for Carbapenem-Based Antibiotics was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Carbapenem-Based Antibiotics was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Europe market for Carbapenem-Based Antibiotics was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The global key companies of Carbapenem-Based Antibiotics include ACS Dobfar S.p.A, Iterum Therapeutics plc, DAEWOONG PHARMACEUTICAL CO.,LTD, Aurobindo Pharma Ltd, Gland Pharma Limited, Merck & Co., Inc., Sumitomo Dainippon Pharma Co., Ltd., Savior Lifetec and Pfizer Inc., etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Carbapenem-Based Antibiotics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Carbapenem-Based Antibiotics by region & country, by Type, and by Application.

The Carbapenem-Based Antibiotics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Carbapenem-Based Antibiotics.

Market Segmentation